Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Capital Stock (Details Textual)

v3.24.3
Note 4 - Capital Stock (Details Textual)
 9 Months Ended 26 Months Ended
Aug. 05, 2024
shares
Sep. 30, 2024
USD ($)
$ / shares
shares
Sep. 30, 2023
USD ($)
$ / shares
shares
Jun. 30, 2024
USD ($)
$ / shares
shares
Aug. 12, 2024
shares
Dec. 31, 2023
$ / shares
shares
Jan. 04, 2023
USD ($)
Mar. 31, 2022
shares
Apr. 30, 2020
shares
Oct. 31, 2017
shares
Apr. 30, 2016
shares
Common Stock, Shares Authorized (in shares) | shares   40,000,000       40,000,000          
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares   $ 0.001   $ 0.001   $ 0.001          
Common Stock, Shares, Outstanding (in shares) | shares   3,525,079       2,980,900          
Proceeds from Issuance of Common Stock   $ 3,192,618 $ 1,734,326                
Capital on Demand Sales Agreement [Member] | JonesTrading Institutional Services LLC [Member]                      
Equity Offering, Maximum Offering Amount             $ 6,505,642        
Proceeds from Issuance of Common Stock, Net     $ 1,467,333 $ 5,446,975              
Equity Offering, Remaining Amount Available       $ 1,058,667              
Stock Issued During Period, Shares, New Issues (in shares) | shares   509,061 173,124                
Shares Issued, Price Per Share (in dollars per share) | $ / shares   $ 6.45 $ 8.85                
Proceeds from Issuance of Common Stock   $ 3,194,310 $ 1,493,205                
Payments of Stock Issuance Costs   $ 81,932 38,312                
Legal Fees     $ 25,872                
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member]                      
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) | shares 7,100,000     5,100,000 1,420,000     1,020,000 620,000 320,000 140,000
Common Stock, Shares, Outstanding (in shares) | shares       17,601,827 3,520,427            
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member] | Reverse Stock Split [Member]                      
Stockholders' Equity Note, Stock Split, Conversion Ratio 5